Agaimy Abbas, Michal Michael, Abdelsatir Ali, Abdelsatir Azza A, Abdulrahim Sawsan, Laco Jan, Ihrler Stephan, Tögel Lars, Stoehr Robert, Bishop Justin A, Din Nasir Ud, Michal Michal
Institute of Pathology, University Hospital, Erlangen, Germany.
Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Prague.
Am J Surg Pathol. 2025 Feb 1;49(2):104-112. doi: 10.1097/PAS.0000000000002334. Epub 2024 Nov 27.
TFE3 rearrangements characterize histogenetically, topographically, and biologically diverse neoplasms. Besides being a universal defining feature in alveolar soft part sarcoma (ASPS) and clear cell stromal tumor of the lung, TFE3 fusions have been reported in subsets of renal cell carcinoma, perivascular epithelioid cell tumor (PEComa), epithelioid hemangioendothelioma and ossifying fibromyxoid tumors. TFE3 -related neoplasms are rare in the head and neck and may pose diagnostic challenges. We herein describe 22 TFE3 fusion neoplasms affecting 11 males and 11 females aged 4 to 79 years (median, 25) and involving different head and neck sites: sinonasal cavities (n = 8), tongue (n = 4), oral cavity/oropharynx (n = 3), salivary glands (n = 2), orbit (n = 2), and soft tissue or unspecified sites (n = 3). Based on morphology and myomelanocytic immunophenotype, 10 tumors qualified as ASPS, 7 as PEComas (3 melanotic; all sinonasal), and 5 showed intermediate (indeterminate) histology overlapping with ASPS and PEComa. Immunohistochemistry for TFE3 was homogeneously strongly positive in all cases. Targeted RNA sequencing/FISH testing confirmed TFE3 fusions in 14 of 16 successfully tested cases (88%). ASPSCR1 was the most frequent fusion partner in ASPS (4 of 5 cases); one ASPS had a rare VCP::TFE3 fusion. The 6 successfully tested PEComas had known fusion partners as reported in renal cell carcinoma and PEComas ( NONO, PRCC, SFPQ , and PSPC1 ). The indeterminate tumors harbored ASPSCR1::TFE3 (n = 2) and U2AF2::TFE3 (n = 1) fusions, respectively. This large series devoted to TFE3-positive head and neck tumors illustrates the recently proposed morphologic overlap in the spectrum of TFE3 -associated mesenchymal neoplasms. While all PEComas were sinonasal, ASPS was never sinonasal and occurred in diverse head and neck sites with a predilection for the tongue. The indeterminate (PEComa-like) category is molecularly more akin to ASPS but shows different age, sex, and anatomic distribution compared with classic ASPS. We report VCP as a novel fusion partner in ASPS and PSPC1 as a novel TFE3 fusion partner in PEComa (detected in one PEComa). Future studies should shed light on the most appropriate terminological subtyping of these highly overlapping tumors.
TFE3重排特征在于组织发生、拓扑结构和生物学特性各异的肿瘤。除了是肺泡软组织肉瘤(ASPS)和肺透明细胞间质瘤的普遍定义特征外,TFE3融合在肾细胞癌、血管周上皮样细胞瘤(PEComa)、上皮样血管内皮瘤和骨化性纤维黏液样肿瘤的亚组中也有报道。TFE3相关肿瘤在头颈部罕见,可能带来诊断挑战。我们在此描述了22例TFE3融合肿瘤,累及11名男性和11名女性,年龄4至79岁(中位数25岁),涉及头颈部不同部位:鼻窦腔(n = 8)、舌(n = 4)、口腔/口咽(n = 3)、唾液腺(n = 2)、眼眶(n = 2)以及软组织或未明确部位(n = 3)。基于形态学和肌黑素细胞免疫表型,10例肿瘤符合ASPS,7例为PEComa(3例含黑色素;均位于鼻窦),5例显示与ASPS和PEComa重叠的中间(不确定)组织学特征。所有病例中TFE3免疫组化均呈均匀强阳性。靶向RNA测序/FISH检测在16例成功检测的病例中有14例(88%)证实存在TFE3融合。ASPSCR1是ASPS中最常见的融合伴侣(5例中有4例);1例ASPS有罕见的VCP::TFE3融合。6例成功检测的PEComa具有肾细胞癌和PEComa中报道的已知融合伴侣(NONO、PRCC、SFPQ和PSPC1)。不确定肿瘤分别含有ASPSCR1::TFE3(n = 2)和U2AF2::TFE3(n = 1)融合。这一关于TFE3阳性头颈部肿瘤的大型系列研究说明了最近提出的TFE3相关间叶性肿瘤谱中的形态学重叠。虽然所有PEComa均位于鼻窦,但ASPS从未位于鼻窦,而是发生在头颈部不同部位,以舌部最为常见。不确定(PEComa样)类别在分子上更类似于ASPS,但与经典ASPS相比,其年龄、性别和解剖分布不同。我们报告VCP是ASPS中的一种新型融合伴侣,PSPC1是PEComa中的一种新型TFE3融合伴侣(在1例PEComa中检测到)。未来的研究应阐明这些高度重叠肿瘤最合适的术语亚型分类。